Research Article

Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

Chengchun Tang,1 Hao Qian,2 Dong Wang,1 Yong Qiao,1 and Gaoliang Yan1

1 Department of Cardiology, Zhongda Hospital, Nanjing, China
2 Southeast University Medical School, Nanjing, China

Correspondence should be addressed to Chengchun Tang; tangchengchun@hotmail.com

Received 3 April 2019; Accepted 19 May 2019; Published 28 May 2019

Backgrounds. Previous studies have reported a relationship between serum total bilirubin (STB) and coronary artery disease (CAD). However, the relationship between STB and prognosis of patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) remains inconclusive. The present study aimed to evaluate the relationship between STB level and prognosis of PCI in patients with ACS. Methods. In total, 2850 ACS patients who underwent PCI at the Affiliated Zhongda Hospital of Southeast University from June 2009 to Jan 2017 were included in the study. Twenty-four-hour STB, 30-day, and 1-year postoperative major adverse cardiovascular events (MACE) were recorded. Subjects were assigned to one of three groups based on STB: Group A (STB ≤ 9.6 μmol/L), Group B (9.7 μmol/L < STB ≤ 15.4 μmol/L), and Group C (STB ≥ 15.5 μmol/L). COX survival analysis was subsequently used to investigate the relationship between the incidence of MACE and STB in the three groups. Results. A total of 2770 subjects were successfully followed up; within 1 year after PCI, 115 (4.15%) subjects died and 191 (6.90%) subjects experienced MACE. One-year follow-up results showed that the incidence of MACE decreased significantly as STB increased; the risk of Group A was 2.002 times that of Group C (95% CI: 1.342-2.986). Cardiac mortality also decreased with increasing STB; the risk of Group A was 3.403 times that of Group C (95% CI: 1.319-8.785). Conclusion. Lower mortality and MACE incidence rates were found in patients with higher STB within 1 year. Therefore, STB is highly recommended as an independent long-term prognosis predictor of PCI in patients with ACS.

1. Introduction

Acute coronary syndrome (ACS) refers to a spectrum of clinical presentations caused by acute myocardial ischemia [1]. It is believed that the rupture or erosion of unstable atherosclerotic plaques is the main pathological basis of the incidence of ACS. At present, percutaneous coronary intervention (PCI) is the principal revascularization strategy employed in the treatment of ACS. The prognosis of PCI in patients with ACS is a key clinical issue, and some studies have indicated that C-reactive protein (CRP), troponin (Tn), and D-dimers are associated with the prognosis [2]; however, a gold standard has not been established.

A large number of domestic and foreign studies have found that STB has antioxidant, free-radical scavenging [3, 4], and antiatherosclerosis effects [5] and is negatively correlated with the incidence and prognosis of coronary atherosclerotic heart disease [6]. However, few studies have investigated the relationship between STB and prognosis of PCI in patients with ACS, and a certain degree of controversy exists in the reported results [7–9]. Therefore, the present study aimed to investigate the relationship between STB and the prognosis of PCI in patients with ACS.

2. Materials and Methods

2.1. Study Population. This study is a retrospective study of 2,850 consecutive patients diagnosed of ACS from June 2009 to Jan 2017 in Zhongda Hospital. The inclusion criteria are as
follows: (1) diagnosed as ACS according to the World Health Organization standards; (2) PCI was performed after admission. The exclusion criteria are as follows: (1) life expectancy is less than 1 year due to diseases such as malignant tumors; (2) have liver and gallbladder diseases such as hepatitis and gallstones; and (3) subjects with serum STB \( > 34.2 \mu \text{mol/L} \) (2 mg/dl) were excluded due to possible chronic liver disease or Gilbert's syndrome [10].

2.2. Baseline Information and Laboratory Examinations. For all subjects, general clinical data and laboratory and imaging results were entered; clinical data were from the hospital medical record system. All blood tests were performed at the Department of Clinical Laboratory, Affiliated Zhongda Hospital of Southeast University. All patients underwent color Doppler echocardiography (performed at the Color Ultrasound Room, Department of Cardiology, Zhongda Hospital) within 72 hours of admission, and the left ventricular ejection fractions (LVEF) were recorded.

2.3. Follow-Up and Study Endpoints. Of 2,850 patients, 2,770 ones completed 1 year of follow-up. Follow-up was conducted through outpatient visits or by phone. The primary endpoint was cardiac death and the secondary endpoint was other MACE; for each event, the time of event occurrence was recorded. MACE include cardiac death, myocardial infarction, revascularization, and stent thrombosis.

2.4. Data Analysis. The 2770 subjects were assigned to one of three groups according to the STB range: Group A: 923 subjects (STB \( \leq 9.6 \mu \text{mol/L} \)), Group B: 924 subjects (9.7 \( \mu \text{mol/L} < \text{STB} \leq 15.4 \mu \text{mol/L} \)), and Group C: 923 subjects (STB \( \geq 15.5 \mu \text{mol/L} \)). Data analysis was performed using SAS (9.4, North Carolina State University). For quantitative data that followed a normal distribution, comparison between multiple groups was performed by analysis of variance; for data that followed a nonnormal distribution, comparison between multiple groups was performed by rank comparison tests. For categorical variables, the chi-square test was used to compare the composition ratios among the groups. Multivariate analysis and survival analysis were, respectively, performed using the COX proportional hazards model for those indicators that are meaningful after univariate analysis. Statistical significance was defined as \( p < 0.05 \).

3. Results

The 2770 subjects were divided into three equal groups. Group A included 923 patients (mean age, 60 ± 11.47 years; males, 69.88%), Group B included 924 patients (mean age, 60 ± 11.32 years; males, 69.05%), and Group C had 923 patients (mean age, 60 ± 11.48 years; males, 70.64%). The baseline data in Table 1 shows that there were no statistical differences in age, sex, and BMI among the three groups, whereas the differences in other variables such as diabetes, renal insufficiency, troponin, HBA1C, STB, serum direct bilirubin (SDB), ALT, aspirin, and statins were statistically significant.

As shown in Tables 2 and 3, there was no significant difference in MACE incidence and cardiac mortality between the three groups within 30 days. The results of one-year follow-up had also been shown in Tables 2 and 3; as we can see, the incidence of MACE in patients with lower STB was significantly higher than those in patients with higher STB; the risk of Group A was 2.002 times that of Group C (95% CI: 1.342–2.986). At the same time, the risk of Group A was 3.403 times that of Group C (95% CI: 1.319–8.785) regarding cardiac death.

TN, AST, and LVEF were found to be independent predictors of death within 1 year in patients, with TN positively correlated and LVEF and AST negatively correlated to the risk of cardiac death.

Table 4 presents an analysis of the difference in STB level among patients with different diseases. The results show that only diabetes had an effect on the STB levels of the ACS patients. The STB levels of the ACS patients without diabetes were higher than those of the ACS patients with diabetes (p=0.028).

4. Discussion

The present study found that STB was not significantly related to the occurrence of MACE and cardiac death within 30 days but was significantly negatively correlated within 1 year. Therefore, we believe that STB can be used as an independent predictor of long-term prognosis after PCI in ACS patients.

At present, the mainstream view of atherosclerosis is that it is mainly associated with an inflammatory injury of the vascular endothelial cells [10–13]. Several studies have asserted that the possible reason for which the incidence and mortality of coronary heart disease are correlated with total bilirubin concentration is that a reduced serum STB indicates the presence of an inflammatory response [14]. Heme oxygenase (HO) is the rate-limiting enzyme in the series of reactions and plays the essential role in the formation of bilirubin. Of two isoforms of HO, elevated expression levels of the HO-1 in response to several stimuli provide cardioprotection by anti-inflammatory, antiapoptotic, anti-proliferative, and antithrombotic effect [15]. The low levels of bilirubin may partially mirror an impaired HO-1 response to vascular injury, resulting in a reduced antioxidant and anti-inflammatory ability of body, which links lower STB and higher risk of long-term mortality in coronary artery disease (CAD) patients [10]. The results of a study by Gululu et al. indicated that bilirubin may indirectly improve coronary microvascular dysfunction and impaired coronary flow reserve through its anti-inflammatory properties, thereby reducing the incidence and development of coronary heart disease [16].

In ACS patients, the coronary arteries are severely narrowed or even completely blocked. After the blood vessels have been opened by PCI, reperfusion injury may occur when blood flow is restored to ischemic cardiac cells. The peroxidation effects caused by free radicals have been regarded as key mechanisms of reperfusion injury [17]. Oxidative stress is a stress-induced chronic inflammatory response that arises in cells after vascular endothelial injury. The reactive oxygen
Table 1: Demographic, clinical, and laboratory characteristics according to STB.

| Variable                      | Group A (N=923) | Group B (N=924) | Group C (N=923) | P-value |
|-------------------------------|-----------------|-----------------|-----------------|---------|
| Age, year                     | 60 ± 11.47      | 60 ± 11.32      | 60 ± 11.48      | 0.314   |
| Men, n (%)                    | 645 (69.88%)    | 638 (69.05%)    | 652 (70.64%)    | 0.757   |
| BMI, kg/m²                    | 0.323           |                 |                 |         |
| Lower than normal, n (%)      | 315 (38.60%)    | 318 (41.68%)    | 283 (36.71%)    |         |
| Normal, n (%)                 | 434 (53.19%)    | 386 (50.59%)    | 430 (55.77%)    |         |
| Higher than normal, n (%)     | 67 (8.21%)      | 59 (7.73%)      | 58 (7.52%)      |         |
| Clinical variables            |                 |                 |                 |         |
| Hypertension, n (%)           | 585 (63.38%)    | 561 (60.71%)    | 551 (59.70%)    | 0.245   |
| Diabetes, n (%)               | 177 (19.22%)    | 126 (13.76%)    | 144 (15.67%)    | 0.006   |
| Smoking, n (%)                | 418 (46.42%)    | 446 (49.06%)    | 433 (47.53%)    | 0.483   |
| Hyperlipidemia, n (%)         | 322 (34.92%)    | 302 (32.68%)    | 305 (33.08%)    | 0.554   |
| Renal insufficiency, n (%)    | 508 (55.52%)    | 448 (48.85%)    | 491 (53.60%)    | 0.013   |
| LVEF, n (%)                   | 50.89 ± 11.13   | 50.88 ± 11.20   | 50.75 ± 10.92   | 0.954   |
| Laboratory values             |                 |                 |                 |         |
| Troponin, ng/mL               | 0.40 (0.03, 3.6) | 1.20 (0.31, 4.70) | 0.98 (0.03, 4.60) | 0.024   |
| Triglycerides, mmol/l         | 1.78 ± 1.30     | 1.75 ± 1.20     | 1.70 ± 1.09     | 0.290   |
| LDL, mmol/l                   | 2.68 ± 0.72     | 2.75 ± 0.80     | 2.67 ± 0.75     | 0.067   |
| HDL, mmol/l                   | 1.91 ± 0.33     | 1.20 ± 0.32     | 1.20 ± 0.31     | 0.723   |
| TC, mmol/l                    | 4.65 ± 1.01     | 4.71 ± 1.04     | 4.61 ± 1.00     | 0.094   |
| HBA1C, n (%)                  | 6.34 ± 1.91     | 5.89 ± 1.87     | 5.87 ± 1.79     | 0.002   |
| Hemoglobin, g/L               | 136.34 ± 16.96  | 137.84 ± 16.70  | 137.82 ± 16.68  | 0.091   |
| Platelet, n/mm³               | 230.51 ± 62.02  | 226.03 ± 62.09  | 226.23 ± 64.24  | 0.223   |
| STB, μmol/l                   | 6.73 ± 2.00     | 12.64 ± 1.61    | 17.76 ± 1.41    | <.001   |
| SDB, μmol/l                   | 3.52 ± 1.56     | 4.15 ± 1.18     | 4.53 ± 1.61     | <.001   |
| AST, u/L                      | 28 (19, 35)     | 29 (19, 37)     | 29 (21, 37)     | 0.052   |
| ALT, u/L                      | 30 (19, 40)     | 32 (21, 43)     | 32 (20, 43)     | 0.007   |
| Previous medications          |                 |                 |                 |         |
| ACEI/ARB, n (%)               | 296 (32.22%)    | 286 (30.25%)    | 277 (30.01%)    | 0.633   |
| β-blocker, n (%)              | 249 (26.98%)    | 233 (25.22%)    | 241 (26.11%)    | 0.690   |
| Aspirin, n (%)                | 283 (30.66%)    | 432 (46.75%)    | 417 (45.18%)    | <.001   |
| Statins, n (%)                | 322 (34.89%)    | 453 (49.03%)    | 435 (47.13%)    | <.001   |

LVEF: left ventricular ejection fraction; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TC: total cholesterol; STB: serum total bilirubin; SDB: serum direct bilirubin; AST: aspartate aminotransferase; ACEI: angiotensin-converting enzyme inhibitor; and ARB: angiotensin II receptor blockade.

Table 2: The COX proportional hazards model analyses predictors for MACE within 30 days and 1 year.

| Variables                  | 30 days        |           | 1 year       |           |
|----------------------------|----------------|-----------|--------------|-----------|
|                            | HR (95% CI)    | P-value   | HR (95% CI)  | P-value   |
| STB group                  |                |           |              |           |
| Group C                    | -              | -         | -            | -         |
| Group B                    | 0.956 (0.582-1.570) | 0.859     | 1.139 (0.746-1.740) | 0.546     |
| Group A                    | 1.046 (0.625-1.750) | 0.865     | 2.002 (1.342-2.986) | <.001     |
| Troponin                   | 1.079 (1.050-1.109) | <.001     | 1.071 (1.047-1.095) | <.001     |
| LVEF                       | 0.966 (0.949-0.983) | <.001     | 0.947 (0.935-0.960) | <.001     |
| AST                        | 0.998 (0.996-0.999) | 0.014     | 0.995 (0.992-0.998) | 0.002     |

LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase.
Table 3: The COX proportional hazards model analyses predictors for cardiac death within 30 days and 1 year.

| Variables   | 30 days          | 1 year          |
|-------------|------------------|-----------------|
|             | HR (95% CI)      | P-value         | HR (95% CI)      | P-value         |
| TBIL group  |                  |                 |                 |                 |
| Group C     | -                | -               | -                | -               |
| Group B     | 0.355 (0.084-1.505) | 0.160          | 0.659 (0.201-2.161) | 0.491          |
| Group A     | 2.148 (0.724-6.372) | 0.168          | 3.403 (1.319-8.785) | 0.011          |
| Troponin    | 1.143 (1.074-1.216) | < .001         | 1.126 (1.070-1.185) | < .001         |
| LVEF        | 0.932 (0.893-0.973) | 0.002          | 0.919 (0.887-0.953) | < .001         |
| AST         | 0.969 (0.940-1.000) | 0.049          | 0.982 (0.965-0.999) | 0.042          |
| Hypertension| 0.255 (0.077-0.846) | 0.026          | -                | -               |

LVEF: left ventricular ejection fraction; AST: aspartate aminotransferase.

Table 4: STB of patients that have each of other diseases.

| Disease              | STB (mmol/L) | Z     | P     |
|----------------------|--------------|-------|-------|
|                      | None         | With  |       |
| Hypertension         | 12.8 (8.9-16.7) | 12.5 (8.1-16.4) | -1.634 | 0.202 |
| Hyperlipidemia       | 12.6 (8.5-16.6) | 12.6 (8.3-16.3) | -1.226 | 0.220 |
| CAD                  | 12.5 (8.9-16.3) | 12.6 (8.3-16.5) | -0.833 | 0.405 |
| Diabetes             | 12.7 (8.6-16.6) | 12.2 (7.8-16.3) | -2.200 | 0.028 |
| CED                  | 12.6 (8.3-16.4) | 12.8 (8.9-16.8) | -1.511 | 0.131 |
| RI                   | 12.6 (8.9-16.4) | 12.6 (8.4-16.6) | -1.531 | 0.130 |

CAD: cardiovascular disease; CED: cerebrovascular disease; RI: renal insufficiency; none: patients without the disease; and with: patients with the disease.

Some studies have reported a significant acceleration of coronary artery restenosis, which commonly occurs 3-6 months after angioplasty in patients who underwent PCI. Smooth muscle cell proliferation and migration have been regarded as key mechanisms for the occurrence of post-PCI restenosis [6]. Öllinger et al. found that bilirubin can inhibit the proliferation of vascular smooth muscle cells, thereby reducing the extent of vascular stenosis [20]. A study by Kuwano et al. also indicated that higher concentrations of bilirubin can reduce the incidence of coronary in-stent restenosis through its inhibitory effects on vascular smooth muscle cell proliferation [21].

Besides the aforementioned mechanisms, we believe that the negative correlation between STB and prognosis in ACS patients shown by the present study may also be due to the endothelial function-enhancing effects of bilirubin. A study by Erdogan et al. indicated that patients with chronic total coronary occlusion who had higher STB within the normal range had better collateral development compared with patients with lower STB, which is suggestive of the endothelial function-enhancing effects of bilirubin [22]. In a study by Yoshino et al., it was also reported that patients with higher bilirubin concentrations may have better endothelial function, which provides resistance against the impairment of coronary artery endothelial function [23].

This study found that STB was inversely related to the patient’s long-term prognosis, but this correlation was not linear. Compared with patients in the hyperbilirubin group, the incidence of MACE was significantly higher in the lower bilirubin group within 1 year, but not in the middle bilirubin group. In addition, the follow-up results within 30 days showed no statistical difference between the three groups, which may be due to the short-term stress response caused by the occurrence of ACS and surgery, which masked the protective effect of hyperbilirubin, so the difference between groups was not obvious in the short term.

There is still some controversy about the relationship between STB and the prognosis in ACS patients. Kaya et al. demonstrated that STB positively correlated with the burden of coronary atherosclerosis in both STEMI and non-STEMI so that elevated STB was independently associated with higher incidence of short-term mortality following AMI [24]. Sang-Ryul Chung et al. find that STB is a powerful prognostic marker; inclusion of this can improve prediction of in-hospital MACE in patients with STEMI undergoing primary PCI [25]. However, studies of Zhang et al. show that high STB concentration is associated with lower MACE in patients with ACS after PCI [26]. In another study, Yao et al. demonstrate that low STB before PCI is an independent
subject is required to enhance the credibility of such studies. Therefore, follow-up involving longer durations and more follow-up durations were not standardized across studies. While other studies focused on STEMI or NSTEMI patients; study population in the present study included ACS patients, be inadequate and, thus, lack representativeness. Secondly, follow-up involving longer durations and more subjects is required to enhance the credibility of such studies.

The study also found that Tn, AST, and LVEF are always associated with patients with MACE and cardiac mortality. Among them, Tn is positively correlated: the higher the patient’s Tn, the worse the prognosis, and Tn reflects the degree of myocardial damage in patients, which is consistent with the results of the study. LVEF reflects the patient’s cardiac function. The higher the LVEF, the smaller the cardiac function damage and the better the prognosis. AST is also a marker of myocardial damage, mainly increases in the case of cardiac injury, and its relationship with the prognosis of patients remains to be further studied.

The present study had several limitations. Firstly, there was only single bilirubin data at admission; no repeated testing was done during long-term follow-up, which may have resulted in biases in the study results. Secondly, as this was a single-center clinical study, population limitations may exist in the cases studied, and the conclusions derived from the study may differ from certain multicenter studies. Thirdly, the follow-up period in this study was limited to 1 year, which is not entirely representative of the prognosis in the subjects. Therefore, further follow-up and investigation are required.

5. Conclusion

The results of this study indicated that MACE and cardiogenic mortality in the higher bilirubin group were significantly lower than those in the lower bilirubin group within 1 year. Therefore, STB is highly recommended as an independent predictor of long-term prognosis in ACS patients.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

[1] C. W. Hamm, J.-P. Bassand, S. Agewall et al., “ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 32, no. 23, pp. 2999–3054, 2011.

[2] H.-J. Hwang, S.-W. Lee, and S.-H. Kim, “Relationship between bilirubin and C-reactive protein,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1823–1828, 2011.

[3] B. Bakrania, E. F. Du Toit, K.-H. Wagner, J. P. Headrick, and A. C. Culmer, “Pre- or post-ischemic bilirubin dithiate treatment reduces oxidative tissue damage and improves cardiac function,” International Journal of Cardiology, vol. 202, pp. 27–33, 2016.

[4] K.-F. Zhu, Y.-M. Wang, Y.-Q. Wang, and N.-F. Wang, “The relationship between serum levels of total bilirubin and coronary plaque vulnerability,” Coronary Artery Disease, vol. 27, no. 1, pp. 52–58, 2016.

[5] N. Gupta, T. Singh, R. Chaudhary et al., “Bilirubin in coronary artery disease: cytotoxic or protective?” World Journal of Gastrointestinal Pharmacology and Therapeutics, vol. 7, no. 4, pp. 469–476, 2016.

[6] M. Stojanov, A. Stefanovic, and G. Dzingalasevic, “Total bilirubin in young men and women: association with risk markers for cardiovascular diseases,” Clinical Biochemistry, vol. 46, no. 15, pp. 1516–1519, 2013.

[7] M. Gul, H. Uyarel, M. Ergelen et al., “Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention,” American Journal of Cardiology, vol. 110, no. 2, pp. 166–171, 2013.

[8] S. Wei, L. Mao, B. Liu, and L. Zhong, “Serum biomarkers and the prognosis of AMI patients,” Herz, vol. 39, no. 3, pp. 384–389, 2014.

[9] H. Acet, F. Ertas, M. A. Akı et al., “A novel predictor of infarct-related artery patency before percutaneous intervention and inhospital outcomes for ST-segment elevation myocardial infarction patients: serum bilirubin level,” Advances in Interventional Cardiology, vol. 2, pp. 91–97, 2014.

[10] F.-Y. Huang, Y. Peng, B.-T. Huang et al., “The correlation between serum total bilirubin and outcomes in patients with different subtypes of coronary artery disease,” Clinica Chimica Acta, vol. 465, pp. 101–105, 2017.

[11] M. Gul, A. K. Kalkan, and H. Uyarel, “Serum bilirubin: a friendly or an enemy against cardiovascular diseases?” Journal of Critical Care, vol. 29, no. 2, pp. 305-306, 2013.

[12] M. E. Jørgensen, C. Torp-Pedersen, N. Finer et al., “Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 24, no. 6, pp. 656–662, 2014.

[13] J. Yu, J.-L. Han, G.-S. Wang, L.-J. Guo, and W. Gao, “Serum total bilirubin levels and disease severity in patients with stable coronary artery disease,” Herz, vol. 42, no. 4, pp. 403–410, 2017.

[14] T. Inoue, N. Sonoda, S. Hiramatsu, S. Kimura, Y. Ogawa, and T. Inoguchi, “Serum bilirubin concentration is associated with left ventricular remodeling in patients with type 2 diabetes mellitus: a cohort study,” Diabetes Therapy, vol. 9, no. 1, pp. 331–338, 2018.

[15] L. E. Fredenburgh, A. A. Merz, and S. Cheng, “Haemooxygenase signalling pathway: Implications for cardiovascular disease,” European Heart Journal, vol. 36, no. 24, pp. 1512–1518, 2015.

[16] H. Gullu, D. Erdogan, D. Tok et al., “High serum bilirubin concentrations preserve coronary flow reserve and coronary
microvascular functions,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2289–2294, 2005.

[17] T. Ha, L. Liu, J. Kelley, R. Kao, D. Williams, and C. Li, “Toll-like receptors: new players in myocardial ischemia/reperfusion injury,” Antioxidants & Redox Signaling, vol. 15, no. 7, pp. 1875–1893, 2011.

[18] M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.

[19] K. Daub, P. Seizer, K. Stellos et al., “Oxidized LDL-activated platelets induce vascular inflammation,” Seminars in Thrombosis and Hemostasis, vol. 36, no. 2, pp. 146–156, 2010.

[20] R. Öllinger, M. Bilban, A. Erat et al., “A natural inhibitor of vascular smooth muscle cell proliferation,” Circulation, vol. 112, no. 7, pp. 1030–1039, 2005.

[21] T. Kuwano, S.-I. Miura, K. Shirai et al., “Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 7, pp. 574–583, 2011.

[22] T. Erdoğan, Y. Çiček, S. A. Kocaman et al., “Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion,” Internal Medicine, vol. 51, no. 3, pp. 249–255, 2012.

[23] S. Yoshino, S. Hamasaki, S. Ishida et al., “Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients,” Journal of Atherosclerosis and Thrombosis, vol. 18, no. 5, pp. 403–412, 2011.

[24] M. G. Kaya, O. Sahin, M. Akpek et al., “Relation between serum total bilirubin levels and severity of coronary artery disease in patients with non-ST-segment elevation myocardial infarction,” Angiology, vol. 65, no. 3, pp. 245–249, 2014.

[25] S.-R. Chung, T.-H. Yang, H.-C. Shin et al., “Initial total bilirubin and clinical outcome in patients with ST- Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents,” Circulation Journal, vol. 80, no. 6, pp. 1437–1444, 2016.

[26] X. Zhang, T. Sun, L. C. Kan et al., “Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention,” Clinical & Investigative Medicine, vol. 37, no. 4, pp. E345–E351, 2014.

[27] H. M. Yao, D. L. Shen, X. Y. Zhao et al., “Prognostic value of total bilirubin in patients with angina pectoris undergoing percutaneous coronary intervention,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 9, pp. 15930–15939, 2015.